ABG Sundal Collier acted as financial advisor in connection with the SEK 35m financing in Ascelia Pharma AB

On 4 February 2024, Ascelia Pharma AB (“Ascelia Pharma” or the “Company”), a biotech company focused on improving the life of people living with rare cancer conditions, announced that the Company has successfully secured SEK 35m in financing from Formue Nord Fokus A/S. The financing is composed of a directed issue of convertibles of SEK 15m and a loan facility of up to SEK 20m. The financing ensures financial and strategic flexibility and extends the cash runway into the second quarter of 2025, covering both the ongoing re-evaluation of images from the Phase 3 study with Orviglance, and completion of time critical activities for the New Drug Application (NDA) for the US Food and Drug Administration (FDA).
Ascelia Pharma has two assets in clinical development with the potential to improve lives for people living with rare cancer conditions. Headline results from the Phase 3 study with the first-in-class, orphan liver imaging drug candidate, Orviglance®, are expected by May 2024. The Company’s shares are listed in Sweden on Nasdaq Stockholm Small Cap.